Skip to content
Search our Site
Search our site
Search our site
My PD Journey
About the EPDA
Political affairs and policy
Medical and pharmaceutical
Political and policy
World PD Day News
Resources and publications
Copy of Home
Rotigotine in Advanced Parkinson's Disease Shows Positive Trial Results
Phase III trial results shows statistically significant and clinically relevant reduction in 'off' time. The results support the favorable data of previous trials with rotigotine.
02 December 2005
Neupro® Receives Positive Opinion from European CHMP for the Treatment of Early Parkinson's Disease
Clinical trials have shown efficacy and safety in early Parkinson's disease patients and a potential for long term benefit. First market launches of the Parkinson's patch within Europe will be in the first half of 2006.
01 December 2005
Initiation of largest disease modification trial to study effect of Azilect® in slowing progression of Parkinson's Disease
The largest clinical study to investigate disease modification in Parkinson's disease (PD) has now enrolled its first patients in Europe and North America.
30 November 2005
Solvay Pharmaceuticals has obtained market authorization for DUODOPA®, the product for treating advanced Parkinson's disease in
DUODOPA® now has a registration in Sweden, Austria, Germany, Denmark, Spain, Finland, France, The Netherlands, Norway, Portugal, Belgium, Greece, Ireland, Italy, United Kingdom, Cyprus, Czech Republic, Estonia, Hungary, Iceland, Liechtenstein, Lithuania, Luxembourg, Latvia, Malta, Poland, Slovenia, and Slovakia;
29 November 2005
DVD of the DBS for Dystonia Conference at Belvoir Castle, Leicestershire - UK's First Deep Brain Stimulation for Dystonia Confer
On Saturday 3rd September 2005, the UK's first conference for people with Dystonia and who have had or are considering a surgical procedure known as Deep Brain Stimulation (DBS), took place at the magnificent Belvoir Castle bringing together leading experts and patients from Belgium, Netherlands, America and across the UK.
16 November 2005
Normal movement restored and new neurons formed in model of Parkinson's disease
Stockholm, Sweden, Nov. 15, 2005 – Two weeks of local administration of sNN0031, a compound under development for Parkinson's disease, normalized movement and restored dopamine balance in a rat model of the disease.
15 November 2005
6th EuroYapmeet Conference: paints brighter future for patients with PD
Carrying as its theme, “Embrace tomorrow. Make the future brightening not frightening,” the 6th European Conference for Younger People with Parkinson's disease (Dublin, 7-9 October) featured a series of upbeat presentations on improving management and developing new therapies.
25 October 2005
The Parkinson's Disease Society (PDS) is pleased to announce the appointment of Steve Ford as its new Chief Executive
Steve, who takes over from Linda Kelly, was previously Chief Executive of South West Kent Primary Care Trust. He has over twenty years experience of working in the health service but this is his first step into the charity sector.
13 October 2005
EPDA President, Mary Baker MBE, receives Patient Advocacy Award presented by Spanish Patients Association
04 October 2005
Treble Reel for Parkinson's Disease Research
On October 8, 2005 the Broesler School of Irish Dance held a Treble Reel for Charity in Carmel, NY at their annual feisanna.
04 October 2005
Back to Top
Add page to PDF basket
Copyright © 2014 EPDA. All Rights Reserved.
Privacy and cookies